Microsoft co-founder Paul Allen diagnosed with cancerNovember 17th, 2009 LONDON - Paul Allen, who founded Microsoft with Bill Gates, has been diagnosed with cancer. Allen, 56, has begun chemotherapy treatment for non-Hodgkin's lymphoma.
Microsoft co-founder Paul Allen diagnosed with non-Hodgkin's lymphoma, undergoing chemotherapyNovember 16th, 2009 more images
more images
Microsoft co-founder Allen treated for lymphoma
SEATTLE — Microsoft co-founder Paul Allen has been diagnosed with non-Hodgkin's lymphoma. In a memo sent to employees, the CEO of Allen's investment firm says the 56-year-old Allen received the diagnosis this month and has begun chemotherapy.
Healthy dose of exercise is good for lymphoma patientsOctober 27th, 2009 WASHINGTON - A regimen of aerobic exercise training can prove fruitful for lymphoma patients receiving chemotherapy, says a new study. Researchers from University of Alberta researchers found that a healthy dose of aerobic exercise training produced significant improvements in physical functioning and overall quality of life benefits in patients with lymphoma.
New finding may provide novel therapeutic targets for depressionOctober 19th, 2009 WASHINGTON - Georgetown University Medical Center researchers have clarified how neurotransmitters like norepinephrine, serotonin, and dopamine, are regulated - a finding that may provide new therapeutic targets for depression. Drugs currently used to treat depression target the regulatory process for neurotransmitters, and while effective in some cases, do not appear to work in other cases.
Potential therapeutic target for lung diseases identifiedOctober 16th, 2009 WASHINGTON - Scientists from Washington University School of Medicine in St. Louis, McGill University have identified a genetic mutation that might open avenues for developing novel treatments for children born with lung distress and chronic obstructive pulmonary disease (COPD).
New therapeutic target for Alzheimer's identifiedOctober 8th, 2009 WASHINGTON - A Purdue University researcher has identified a potential therapeutic target for Alzheimer's disease. Researcher Sandra Rossie, a professor of biochemistry, found that the amount of an enzyme present in neurons can affect the mechanism thought to cause cell death in Alzheimer's disease patients and may have applications for other diseases such as stroke and heart attack.
Gene critical to cancer cell survival identifiedOctober 6th, 2009 WASHINGTON - University of York claim to have identified a gene that appears to play a crucial role in cancer cell survival. The researchers have used a process called RNA interference to target the JNK2 gene in both cancer and healthy cells.
Novel therapeutic target for fatal flu lung complication identifiedSeptember 30th, 2009 WASHINGTON - Researchers from Louisiana State University Health Sciences Center have identified a new target that for preventing fatal flu lung complication. The study showed that the novel target could help prevent acute lung injury resulting in acute respiratory distress syndrome, a highly fatal complication of influenza infection.
Gene that could lead to new therapies for bone marrow disease identifiedSeptember 29th, 2009 WASHINGTON - Scientists from Van Andel Research Institute (VARI) have identified a gene that helps in progression of Myelodysplastic Syndrome (MDS), a bone marrow disease. They believe that the new gene called RhoB could prove to be a therapeutic target for late-stage MDS.
New gene may provide better immune defense against anthraxSeptember 9th, 2009 WASHINGTON - Scientists from University of California have identified a gene in anthrax-causing bacteria that could be used as a potential therapeutic target for the deadly disease. The ClpX gene in bacterium Bacillus anthracis not only contributes to the severity of the anthrax disease but also makes it more difficult for a patient's immune system to fight the infection.
Found: Antibodies to target HIV more effectivelySeptember 4th, 2009 WASHINGTON - The discovery of two powerful new HIV antibodies will help tackle HIV more effectively. Researchers will now try to exploit a newfound vulnerability on the virus to craft novel approaches to designing an AIDS vaccine.
FDA panel says Allos Therapeutics drug will benefit patients with rare form of lymphomaSeptember 2nd, 2009 FDA panel backs Allos Therapeutics' cancer drugWASHINGTON — Federal health experts voted Wednesday in favor of an experimental cancer drug from Allos Therapeutics for patients with a rare form of cancer. A spokeswoman for the Food and Drug Administration said the agency's panel of oncology experts voted 10-4 that the company's drug pralatrexate would likely benefit patients with T-Cell lymphoma.
Scientists imitate viruses to deliver therapeutic genesSeptember 1st, 2009 WASHINGTON - Australian scientists have developed a new gene therapy vector that uses the same machinery as viruses to transport their cargo into cells. David Jans, from the Nuclear Signaling Laboratory at Monash University in Victoria, says that this achievement has raised the hope that one day therapeutic DNA will begin to be transferred to a cell's nucleus far more efficiently than in the past, and thus there will be more effective treatments for several genetic disorders and some types of cancers.
Gene behind gum disease, osteoporosis, arthritis identifiedAugust 31st, 2009 WASHINGTON - An international team of researchers have identified a gene that is common in the development of gum disease, rheumatoid arthritis, and osteoporosis. Experts at Hospital for Special Surgery say that their findings about the gene, called interferon regulator factor-8 (IRF-8), may lead to new treatments in future.
Novel therapeutic target for Parkinson's disease identifiedAugust 29th, 2009 WASHINGTON - Scientists from University of Helsinki Institute of Biotechnology have identified a novel therapeutic target for Parkinson's disease. Lead researcher Professor Raimo K.
